- Home
- LVTX vs OKUR Comparison
LVTX vs OKUR Comparison
Compare LVTX & OKUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- OKUR
- Stock Information
- Founded
- LVTX 2016
- OKUR 2011
- Country
- LVTX Netherlands
- OKUR United States
- Employees
- LVTX N/A
- OKUR N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- OKUR
- Sector
- LVTX Health Care
- OKUR
- Exchange
- LVTX Nasdaq
- OKUR NYSE
- Market Cap
- LVTX 33.9M
- OKUR 34.9M
- IPO Year
- LVTX 2021
- OKUR N/A
- Fundamental
- Price
- LVTX $1.42
- OKUR $2.28
- Analyst Decision
- LVTX Hold
- OKUR Strong Buy
- Analyst Count
- LVTX 3
- OKUR 4
- Target Price
- LVTX $1.75
- OKUR $32.25
- AVG Volume (30 Days)
- LVTX 48.5K
- OKUR 73.0K
- Earning Date
- LVTX 08-19-2025
- OKUR 08-14-2025
- Dividend Yield
- LVTX N/A
- OKUR N/A
- EPS Growth
- LVTX N/A
- OKUR N/A
- EPS
- LVTX N/A
- OKUR N/A
- Revenue
- LVTX $4,990,000.00
- OKUR N/A
- Revenue This Year
- LVTX N/A
- OKUR N/A
- Revenue Next Year
- LVTX N/A
- OKUR N/A
- P/E Ratio
- LVTX N/A
- OKUR N/A
- Revenue Growth
- LVTX N/A
- OKUR N/A
- 52 Week Low
- LVTX $0.85
- OKUR $1.70
- 52 Week High
- LVTX $2.21
- OKUR $20.00
- Technical
- Relative Strength Index (RSI)
- LVTX 52.65
- OKUR N/A
- Support Level
- LVTX $1.33
- OKUR N/A
- Resistance Level
- LVTX $1.67
- OKUR N/A
- Average True Range (ATR)
- LVTX 0.13
- OKUR 0.00
- MACD
- LVTX 0.00
- OKUR 0.00
- Stochastic Oscillator
- LVTX 25.00
- OKUR 0.00
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.